Results 81 to 90 of about 14,094 (223)

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study

Diabetology & Metabolic Syndrome
Background and Aim The association between biliary disorders with weight reduction enhanced by GLP-1RAs was observed frequently, nevertheless, the relative risk of the clinically relevant cholelithiasis was not specified clearly among different GLP-1RAs.
Mohammed Ali Gameil, Elshahat Ali Ahmed Mohamed Yousef, Rehab Elsayed Marzouk, Mohamed H. Emara, Abeer H. Abdelkader, Rasha Ibrahim Salama   +5 more
doaj   +1 more source

Semaglutide exerts neuroprotective effects by blocking the interleukin-17/NOD-like receptor family pyrin domain containing 3-mediated neuroinflammation pathway after traumatic brain injury

Neural Regeneration Research
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, exhibits significant neuroprotective effects in stroke and neurodegenerative diseases.
Bin Zhang, Lu Kong, Yumei Wang, Wei He, Mengshi Yang, Xueling Zhang, Xiyu Chen, Yaxuan Zhang, Baiyun Liu, Miao Bai, Guangzhi Shi   +10 more
doaj   +1 more source

Levodopa Efficacy and GLP‐1 Receptor Agonists

Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez, Christine Girges, Thomas Foltynie, Anne‐Marie Wills   +3 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway

Journal of Cancer Research and Clinical Oncology
Aims Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM ...
Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang   +4 more
doaj   +1 more source

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Molecular Metabolism
Objective: The development of glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has been accompanied by evidence for anti-inflammatory and cytoprotective actions in the heart, blood vessels, kidney, and ...
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, Fiona Cui, Chi Kin Wong, Nikolaj Rittig, Xiemin Cao, Dianne Matthews, Daniel J. Drucker   +8 more
doaj   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

Contractile Effects of Semaglutide in the Human Atrium

Pharmaceutics
Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R agonists are used to treat type 2 diabetes and obesity. It is currently unknown whether semaglutide can directly increase force of contraction (FOC) in the human heart.
Joachim Neumann, Katarína Hadová, Jan Klimas, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Six‐ and Twelve‐Month Changes in Body Composition and 24‐h Energy Expenditure After a Very Low‐Calorie Ketogenic Diet

Obesity, EarlyView.
ABSTRACT Objective This study assessed changes in body composition and 24‐h energy metabolism at 6 and 12 months after initiation of a 1‐month very low‐calorie ketogenic diet (VLCKD) in women with obesity. Methods Seventeen women with obesity who completed a 1‐month VLCKD underwent a 4‐week transition phase with carbohydrate reintroduction, followed by
Alessio Basolo, Paolo Piaggi, Valentina Angeli, Paola Fierabracci, Chiara Bologna, Giordano Paolucci, Guido Salvetti, Luca Chiovato, Jonathan Krakoff, Alberto Landi, Ferruccio Santini   +10 more
wiley   +1 more source